Renal toxicity associated with tenofovir use
Expert Opinion on Drug Safety2010Vol. 9(4), pp. 545–559
Citations Over TimeTop 10% of 2010 papers
Abstract
Severe renal damage associated with TFV use is uncommon and of multifactorial origin. However, mild tubular dysfunction is recognized in a substantial proportion of TFV-treated individuals and tends to increase with cumulative exposure.
Related Papers
- → 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients(2022)21 cited
- → 21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS(2009)6 cited
- → Studies on nephrotoxicity following a single and repeated administration of cis-diamminedichloroplatinum (CDDP) in rats.(1987)8 cited
- → The enhancement of cyclosporin a-induced nephrotoxicity by gentamicin(1983)24 cited
- → 559 COST-EFFECTIVENESS SIMULATION ANALYSIS OF TENOFOVIR DISOPROXIL FUMARATE (TENOFOVIR) IN HBEAG NEGATIVE (-) PATIENTS WITH CHRONIC HEPATITIS-B (CHB) IN ITALY AND FRANCE(2008)6 cited